|
rs2180314
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |
|
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We found no effect of N314D GALT genotype on the risk of borderline ovarian cancer (odds ratio (OR)=0.91; 95% confidence interval (CI)=0.54-1.6) or invasive ovarian cancer (OR=0.78; 95% CI= 0.53-1.2).
|
11936817 |
2002 |
|
rs28362491
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined the potential association between ovarian cancer and 15 SNPs (rs28362491, rs3774932, rs1598856, rs230531, rs230530, rs230528, rs230521, rs230498, rs230539, rs1005819, rs3774956, rs4648055, rs4648068, rs3774964, rs3774968) of the NFKB1 gene using the MassARRAY system.
|
26345753 |
2015 |
|
rs771386507
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We established that <i>TP53</i> "hotspot" mutations (c.659A>G; p.Y220C and c.733G>A; p.G245S) expressed by two different patients' tumors were both immunogenic in the context of HLA-DRB3*02:02.<b>Conclusions:</b> Mutation-reactive T cells infiltrated ovarian cancer metastases at sufficient frequencies to warrant their investigation as adoptive cell therapy.
|
29853601 |
2018 |
|
rs1136905
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We established that <i>TP53</i> "hotspot" mutations (c.659A>G; p.Y220C and c.733G>A; p.G245S) expressed by two different patients' tumors were both immunogenic in the context of HLA-DRB3*02:02.<b>Conclusions:</b> Mutation-reactive T cells infiltrated ovarian cancer metastases at sufficient frequencies to warrant their investigation as adoptive cell therapy.
|
29853601 |
2018 |
|
rs7246045
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed Central European females diagnosed with ovarian cancer (n=95) and controls (n=76) for the occurrence of at least one of three polymorphisms (rs7260002, rs7246045, rs540432391) and their impact on cancer risk.
|
28355589 |
2017 |
|
rs121913279
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs104886003
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs752742313
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs67397200
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05-1.29; P = 3.8 × 10(-4)) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10-1.52; P = 1.8 × 10(-3)).
|
22351618 |
2012 |
|
rs2146323
|
|
|
0.010 |
GeneticVariation |
BEFREE |
VEGF tagSNPs rs3025033 and rs2146323 were not associated with ovarian cancer survival in the Australian sample.
|
20832104 |
2010 |
|
rs3025033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
VEGF tagSNPs rs3025033 and rs2146323 were not associated with ovarian cancer survival in the Australian sample.
|
20832104 |
2010 |
|
rs2424932
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using PCR-RFLP and HRM analyses, we studied the prevalence of the DNMT1 rs8101626, rs2228611 and rs759920, DNMT3A rs2289195, 7590760, rs13401241, rs749131 and rs1550117, and DNMT3B rs1569686, rs2424913 and rs2424932 SNPs in patients with ovarian cancer (n=159) and controls (n=180).
|
23666104 |
2013 |
|
rs2424913
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using PCR-RFLP and HRM analyses, we studied the prevalence of the DNMT1 rs8101626, rs2228611 and rs759920, DNMT3A rs2289195, 7590760, rs13401241, rs749131 and rs1550117, and DNMT3B rs1569686, rs2424913 and rs2424932 SNPs in patients with ovarian cancer (n=159) and controls (n=180).
|
23666104 |
2013 |
|
rs147961867
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using fluorescence-activated cell sorting (FACS) analysis of DNA stained OVACAR3s and terminal deoxynucleotide tranferase-mediated dUTP nick end-labeling (TUNEL), we found that even at concentrations of 1 and 3 µM cisplatin, C16Y at 10 and 25 µg/ml increased the incidence of apoptosis in OVACAR3s by 3-5-fold.
|
21935568 |
2011 |
|
rs7650365
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs in RUVBL1, rs13063604 and rs7650365, were associated with increased risk of serous ovarian cancer [HetOR = 1.42 (1.15-1.74) and the HomOR = 1.63 (1.10-1.42), p-trend = 0.0002] and [HetOR = 0.97 (0.80-1.17), HomOR = 0.74 (0.58-0.93), p-trend = 0.009], respectively.
|
20635389 |
2011 |
|
rs13063604
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs in RUVBL1, rs13063604 and rs7650365, were associated with increased risk of serous ovarian cancer [HetOR = 1.42 (1.15-1.74) and the HomOR = 1.63 (1.10-1.42), p-trend = 0.0002] and [HetOR = 0.97 (0.80-1.17), HomOR = 0.74 (0.58-0.93), p-trend = 0.009], respectively.
|
20635389 |
2011 |
|
rs7526063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs (rs7365052, rs7526063) showed borderline significant inverse associations with ovarian cancer risk; both had very low minor allele frequencies.
|
21629268 |
2011 |
|
rs7365052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs (rs7365052, rs7526063) showed borderline significant inverse associations with ovarian cancer risk; both had very low minor allele frequencies.
|
21629268 |
2011 |
|
rs755378873
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
|
24463159 |
2014 |
|
rs3020450
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the correlation between the polymorphism of estrogen receptor β gene (ESR2) rs3020450 and cancer susceptibility, and explore the epidemiological significance and the effect of ESR2 expression levels on the prognosis of ovarian cancer.
|
31200086 |
2019 |
|
rs2910164
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To examine whether rs2910164 plays any role in breast and/or ovarian cancer, we studied associations between this polymorphism and age of diagnosis in 42 patients with familial breast cancer and 82 patients with familial ovarian cancer.
|
18660546 |
2008 |
|
rs1801133
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively.
|
22669161 |
2012 |
|
rs6917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively.
|
22669161 |
2012 |
|
rs1801155
|
|
|
0.720 |
GeneticVariation |
BEFREE |
To determine whether the excess of colon cancer in some breast-ovarian cancer families is related to the I1307K mutation, we evaluated 264 Ashkenazi Jews from 158 families.
|
9407954 |
1997 |